CVS Quote, Financials, Valuation and Earnings

Biogen has a net margin of 1.68% compared to CVS Health's net margin of 10.87%. CVS Health's return on equity of 6.12% beat Biogen's return on equity of 10.33%.

CVS Health has a consensus price target of $72.26, signalling upside risk potential of 6.91%. On the other hand Biogen has an analysts' consensus of $201.18 which suggests that it could grow by 42.6%. Given that Biogen has higher upside potential than CVS Health, analysts believe Biogen is more attractive than CVS Health.

CVS Health has a beta of 0.537, which suggesting that the stock is 46.292% less volatile than S&P 500. In comparison Biogen has a beta of 0.012, suggesting its less volatile than the S&P 500 by 98.773%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 3.94%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CVS Health pays 73.1% of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health quarterly revenues are $97.7B, which are larger than Biogen quarterly revenues of $2.5B. CVS Health's net income of $1.6B is higher than Biogen's net income of $266.7M. Notably, CVS Health's price-to-earnings ratio is 18.47x while Biogen's PE ratio is 12.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.23x versus 2.12x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of 1.68% compared to CVS Health's net margin of 23.56%. CVS Health's return on equity of 6.12% beat Gilead Sciences's return on equity of 2.5%.

CVS Health has a consensus price target of $72.26, signalling upside risk potential of 6.91%. On the other hand Gilead Sciences has an analysts' consensus of $111.71 which suggests that it could grow by 0.49%. Given that CVS Health has higher upside potential than Gilead Sciences, analysts believe CVS Health is more attractive than Gilead Sciences.

CVS Health has a beta of 0.537, which suggesting that the stock is 46.292% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.213, suggesting its less volatile than the S&P 500 by 78.702%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 3.94%. Gilead Sciences offers a yield of 2.79% to investors and pays a quarterly dividend of $0.79 per share. CVS Health pays 73.1% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

CVS Health quarterly revenues are $97.7B, which are larger than Gilead Sciences quarterly revenues of $7.6B. CVS Health's net income of $1.6B is lower than Gilead Sciences's net income of $1.8B. Notably, CVS Health's price-to-earnings ratio is 18.47x while Gilead Sciences's PE ratio is 300.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.23x versus 4.86x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Humana has a net margin of 1.68% compared to CVS Health's net margin of -2.37%. CVS Health's return on equity of 6.12% beat Humana's return on equity of 7.25%.

CVS Health has a consensus price target of $72.26, signalling upside risk potential of 6.91%. On the other hand Humana has an analysts' consensus of $296.65 which suggests that it could grow by 9.72%. Given that Humana has higher upside potential than CVS Health, analysts believe Humana is more attractive than CVS Health.

CVS Health has a beta of 0.537, which suggesting that the stock is 46.292% less volatile than S&P 500. In comparison Humana has a beta of 0.573, suggesting its less volatile than the S&P 500 by 42.682%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 3.94%. Humana offers a yield of 1.31% to investors and pays a quarterly dividend of $0.89 per share. CVS Health pays 73.1% of its earnings as a dividend. Humana pays out 35.71% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health quarterly revenues are $97.7B, which are larger than Humana quarterly revenues of $29.2B. CVS Health's net income of $1.6B is higher than Humana's net income of -$693M. Notably, CVS Health's price-to-earnings ratio is 18.47x while Humana's PE ratio is 27.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.23x versus 0.28x for Humana. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 1.68% compared to CVS Health's net margin of -117.16%. CVS Health's return on equity of 6.12% beat Moderna's return on equity of -29.09%.

CVS Health has a consensus price target of $72.26, signalling upside risk potential of 6.91%. On the other hand Moderna has an analysts' consensus of $53.44 which suggests that it could grow by 68.81%. Given that Moderna has higher upside potential than CVS Health, analysts believe Moderna is more attractive than CVS Health.

CVS Health has a beta of 0.537, which suggesting that the stock is 46.292% less volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 3.94%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CVS Health pays 73.1% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health quarterly revenues are $97.7B, which are larger than Moderna quarterly revenues of $956M. CVS Health's net income of $1.6B is higher than Moderna's net income of -$1.1B. Notably, CVS Health's price-to-earnings ratio is 18.47x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.23x versus 3.90x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.